A Phase 4 Study to Evaluate the Safety and Tolerability of Higher Infusion Rates of Agalsidase Beta to Shorten Infusion Duration in Fabry Disease: Interim Analysis

Authors: Maryam Banikazemi, Ozlem Goker-Alpan, Khan J. Nedd, Manish Maski, Chase Lee

Published: 2024-10-28

DOI: 10.1681/asn.20249th2t8ga

Keywords: No keywords found.

Abstract:
No abstract found.

Source: